Copyright
©The Author(s) 2020.
World J Cardiol. Dec 26, 2020; 12(12): 615-625
Published online Dec 26, 2020. doi: 10.4330/wjc.v12.i12.615
Published online Dec 26, 2020. doi: 10.4330/wjc.v12.i12.615
Table 1 Baseline demographics and clinical characteristics
| Characteristics | n = 77 |
| Age (mean ± SD), yr | 55 ± 11.8 |
| Men, n (%) | 59 (76.6) |
| Medical history, n (%) | |
| Hypertension | 37 (48.1) |
| Diabetes | 15 (19.48) |
| Smoking | 24 (31.2) |
| Consumption of alcohol | 9 (11.7) |
| Stroke | 2 (2.6) |
| Previous coronary intervention | 4 (5.2) |
| Previous myocardial infarction | 34 (44.2) |
| Cardiac status, n (%) | |
| Stable angina | 30 (39) |
| Unstable angina | 13 (16.9) |
| STEMI | 26 (33.8) |
| NSTEMI | 8 (10.4) |
| Coronary angiogram finding, n (%) | |
| Single-vessel disease | 61 (79.2) |
| Double-vessel disease | 16 (20.8) |
| Triple-vessel disease | 0 (0.0) |
| Heart rate (mean ± SD), bpm | 81.26 ± 12.08 |
| Systolic blood pressure (mean ± SD), mmHg | 134.91 ± 27.51 |
| Diastolic blood pressure (mean ± SD), mmHg | 83.19 ± 13.57 |
| Serum creatinine (mean ± SD), mg/dL | 1.13 ± 0.23 |
| LVEF (mean ± SD), % | 46.38 ± 8.19 |
Table 2 Procedural and lesion characteristics
| Characteristics | n = 77 |
| Access site approach, n (%) | |
| Femoral | 20 (26) |
| Radial | 57 (74) |
| Total number of lesions | 102 |
| Total number of lesions treated with EverProTM | 98 |
| Lesions per patient | 1.32 |
| Stents per patient | 1.27 |
| Lesion location, n (%) | |
| Right carotid artery | 29 (29.6) |
| Left anterior descending artery | 48 (49) |
| Left circumflex artery | 12 (12.2) |
| Obtuse marginal artery | 9 (9.2) |
| Stenosis type, n (%) | |
| De novo | 95 (96.9) |
| In-stent | 3 (3.1) |
| Thrombus load, n (%) | |
| None | 76 (77.6) |
| Mild | 10 (10.2) |
| Moderate | 5 (5.1) |
| Severe | 7 (7.1) |
| ACC/AHA lesion type, n (%) | |
| A | 5 (5.1) |
| B1 | 30 (30.6) |
| B2 | 38 (38.8) |
| C | 25 (25.5) |
| Percent stenosis (mean ± SD) | 88.39 ± 9.30 |
| Stent length (mean ± SD), mm | 18.20 ± 4.34 |
| Stent diameter (mean ± SD), mm | 2.89 ± 0.36 |
| TIMI flow post-procedure, n (%) | |
| TIMI 3 | 98 (100) |
| Discharge medications, n (%) | |
| Aspirin | 77 (100) |
| Clopidogrel | 44 (57.1) |
| Ticlopidine | 2 (2.6) |
| Prasugrel | 3 (3.9) |
| Ticagrelor | 27 (35.1) |
- Citation: Trimukhe R, Vani P, Patel A, Salgotra V. Safety and performance of the EverProTM everolimus-eluting coronary stent system with biodegradable polymer in a real-world scenario. World J Cardiol 2020; 12(12): 615-625
- URL: https://www.wjgnet.com/1949-8462/full/v12/i12/615.htm
- DOI: https://dx.doi.org/10.4330/wjc.v12.i12.615